Increasing the prevalence of Hepatitis B across the globe is major driving the growth of the hepatitis B therapeutics market. Rising incidence of hepatitis B in western Pacific Region and African Region, where 6.2% and 6.1% respectively of the adult population is infected. Furthermore, in Eastern Mediterranean Region, South-East Asia Region, America and European Region 3.3%, 2.0%, 0.7% and 1.6% of the general population is infected, respectively. According to the WHO, increasing prevalence of Hepatitis B in infants infected from their mothers. Hepatitis B is widely spread from mother to child at birth and especially from an infected child to an uninfected child during the first 5 years of life. Recommended 3-dose schedule of hepatitis B vaccine for the prevention of hepatitis B virus.
The Hepatitis B therapeutics market is segmented by therapy, product type, and distribution channel.
On the basis of therapy, the market is segmented into chemotherapy, immunosuppressant therapy, and nucleoside analogue.
Based on product type, the market is segmented into hepatitis b vaccine and anti-viral drugs.
On the basis of distribution channel, the hepatitis B therapeutics market is segmented into hospital pharmacies, retail pharmacies, and online pharmacies.
Geographically, the global hepatitis B therapeutics market is segmented into four major regions such as North America, Europe, Asia Pacific (APAC), and Latin America, Middle East & Africa (LAMEA).
North America is expected to dominate the global hepatitis B therapeutics market. Hepatitis B is the contagious diseases, it is transmitted by having contact with sex workers and sex with multiple partners is boosting the growth of the market. Increasing number of incidence hepatitis B in infants owing to transfer from mother to baby during birth supports the growth of the market.
Europe is expected to be the second leading region in the global hepatitis B therapeutics market in the coming years. Increasing prevalence of hepatitis B owing to less availability of antibiotics in the market and effectiveness of antivirals against hepatitis B infections is propelling the growth of the market. Furthermore, medications and treatment of hepatitis B options are highly expensive thus, increasing per capita is driving the growth of the market in this region.
Asia Pacific (APAC) is expected to grow in the forecast period owing to increasing health awareness and advancement in health care infrastructure is propelling the growth of the market in this region. Hepatitis B medication and treatment is expensive is major restrain in this region.
LAMEA is expecting a steady growth owing to undeveloped healthcare infrastructure. Lack of awareness about the healthy lifestyle is slowing the market in this region. Additionally, Increasing prevalence of hepatitis B is boosting the growth of market. In Middle East Africa improving healthcare infrastructure and government initiative in healthcare infrastructure is growing demand of market.
Some major players in the global hepatitis B therapeutics market include GlaxoSmithKline plc, Abivax SA, F. Hoffmann- La Roche, Novira Therapeutics, Novartis AG, Merck & Co., Bristol-Myers Squibb, and Johnson & Johnson,
In February 2017, Cipla agreement co-exclusive agreement with Serum Institute of India Private Limited (SII), Cipla will market the vaccine for adults while Serum Institute of India will market it for adults and children.